About the Company
Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses. Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts. The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital. In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CERE News
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for ...
Cerevel Therapeutics Holdings Inc (CERE) Shares Decline Despite Market Challenges
COLES N ANTHONY, the Director of Cerevel Therapeutics Holdings Inc, sale 50,000 shares at $41.01 during a trade that took place back on Mar 04 ’24, which means that COLES N ANTHONY is holding 15,638 ...
Cerevel Therapeutics Holdings Inc (CERE) Stock Price and Analyst Predictions
COLES N ANTHONY, the Director of Cerevel Therapeutics Holdings Inc, sale 50,000 shares at $41.01 during a trade that took place back on Mar 04 ’24, which means that COLES N ANTHONY is holding 15,638 ...
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy ...
Cerevel Therapeutics Holdings Inc.
1 Day CERE 0.17% DJIA 0.56% S&P 500 -0.88% Health Care/Life Sciences -0.67% ...
Cerevel Therapeutics Holdings Inc (CERE)
Investing.com - Cerevel Therapeutics Holdings (NASDAQ: CERE) reported first quarter EPS of $-0.67, worse than the analyst estimate of $-0.66. Revenue for the quarter came in at ...
Cerevel Therapeutics Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Cerevel Therapeutics Holdings Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cerevel Therapeutics Holdings Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...